公开(公告)号：US20230052348A1

公开(公告)日：2023-02-16

申请号：US17501075

申请日：2021-10-14

申请人： AMGEN INC.

发明人： Sean P BROWN ,  David Karl BEDKE ,  Michael R. DEGRAFFENREID ,  Jiasheng FU ,  Zhinghong LI ,  Felix GONZALEZ LOPEZ DE TURISO ,  Ana GONZALEZ BUENROSTRO ,  Michael W. GRIBBLE JR. ,  Michael G. JOHNSON ,  Todd J. KOHN ,  Kexue LI ,  Yunxiao LI ,  Mike Elias LIZARZABURU ,  Yosup REW ,  Joshua TAYGERLY ,  Yingcai WANG ,  Xuelei YAN ,  Ming YU ,  Jiang ZHU ,  Manuel ZANCANELLA ,  Xian Yun JIAO ,  Liusheng ZHU ,  Xianghong WANG ,  Julio C. MEDINA ,  Jason A. DUQUETTE ,  Jonathan B. HOUZE ,  Marc VIMOLRATANA ,  Mario G. CARDOZO ,  Alan C. CHENG

IPC分类号： C07D513/10 ,  C07D513/20 ,  C07D515/10

摘要： Provided herein are myeloid cell leukemia 1 protein (Mcl-1) inhibitors, methods of their preparation, related pharmaceutical compositions, and methods of using the same. For example, provided herein are compounds of Formula I, and pharmaceutically acceptable salts thereof and pharmaceutical compositions containing the compounds. The compounds and compositions provided herein may be used, for example, in the treatment of diseases or conditions, such as cancer.